TriSalus Life Sciences, Inc.

TLSI Healthcare Medical Devices

TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

3.63 0.27 −6.92%
Market cap
$240.1M
P/E
0.0×
Fwd P/E
−10.9×
Dividend yield
—
F-score
3/9
Altman Z
−11.34
Beneish M
−5.08
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 4 4
ROE
306.43% 233.25% 529.28% 889.44%
ROA
(226.01%) (235.03%) (114.58%) (110.34%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(298.03%) (309.01%) (97.89%) (113.57%)
Average Days of Receivables
45.39 53.01 42.41 52.30
Free Cash Flow per Share
(0.51) (0.50) (0.39) (0.40)
Free Cash Flow
(22.08) (18.85) (20.26) (23.24)
Other line items

Show all line items

Columns are period end dates